Madrigalв: Dip

: Akero's results showed the potential for cirrhosis reversal, which temporarily overshadowed Madrigal's market position.

Madrigal continues to report positive results from its own clinical trials, including the trial. MadrigalВ Dip

The consensus among firms like TipRanks is that Madrigal’s treatment could become a "blockbuster," supported by its first-mover advantage in the space. : Akero's results showed the potential for cirrhosis

Investment firms, including and Piper Sandler , maintain a bullish outlook despite the price drop: including and Piper Sandler

: Analysts at Piper Sandler recently raised their price target for Madrigal to $400 (up from $336), viewing the competitor data as validation for the entire MASH treatment market rather than a threat.